Junshi Biosciences’ Toripalimab-Bevacizumab Combo Meets Primary Endpoints in HCC Phase III Trial
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has declared a significant milestone with...
Cancer
Sino Biopharmaceutical’s KRAS Inhibitor Garsorasib Earns Breakthrough Designation in China
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has announced that its...
Bayer’s HER2 Targeting Drug BAY 2927088 Earns Breakthrough Designation in China
The Center for Drug Evaluation (CDE) in China has granted Breakthrough Therapy Designation (BTD) to...
Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA)...
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and...
MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...
Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Rightongene Bio Receives NMPA Approval for BCR-ABL P210 Fusion Gene Detection Kit
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a biopharmaceutical company based in China, has announced...
Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...
Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial
Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...
AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...
Varian Medical Gets China Approval for Fourth-Generation Halcyon Radiotherapy System
Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that...
CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...